Brief: Syros Pharmaceuticals Q3 EPS USD -1.43
14/11/2023 12:30
Nov 14 (Reuters) - Syros Pharmaceuticals Q3 operating expenses USD 38.398 million. * Q3 income from operations USD -34.636 million * Q3 net income USD -40.143 million * Q3 revenue USD 3.762 million
Recent news on Syros Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-Elevance, Backblaze, Disney
Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes
U.S. STOCKS ON THE MOVE-Charter Communications, BioNTech, Big US banks
U.S. STOCKS ON THE MOVE-BankUnited, Natera, Adaptimmune
Syros falls after blood cancer drug fails in late-stage trial